|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression multiple interactions |
ISO |
Camptothecin results in decreased expression of ABCB1 mRNA; Camptothecin results in decreased expression of ABCB1 protein Camptothecin inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA] |
CTD |
PMID:10692111 PMID:29356861 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases response to substance multiple interactions |
ISO |
ABCC1 protein results in decreased susceptibility to Camptothecin analog Camptothecin inhibits the reaction [ABCC1 results in decreased susceptibility to Daunorubicin] |
CTD |
PMID:11778547 PMID:12115804 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Acvr1b |
activin A receptor type 1B |
increases methylation |
ISO |
Camptothecin results in increased methylation of ACVR1B gene |
CTD |
PMID:30720231 |
|
NCBI chr 7:132,286,266...132,329,679
Ensembl chr 7:132,286,275...132,329,673
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
decreases response to substance |
ISO |
ADAM19 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105
|
|
G |
Agap1 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 |
increases methylation |
ISO |
Camptothecin results in increased methylation of AGAP1 gene |
CTD |
PMID:30720231 |
|
NCBI chr 9:90,039,720...90,475,196
Ensembl chr 9:90,039,605...90,470,958
|
|
G |
Agrn |
agrin |
increases expression |
ISO |
Camptothecin results in increased expression of AGRN mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003
|
|
G |
Agrp |
agouti related neuropeptide |
decreases response to substance |
ISO |
AGRP mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr19:33,447,992...33,481,602
Ensembl chr19:33,447,992...33,449,584
|
|
G |
Aifm3 |
apoptosis inducing factor, mitochondria associated 3 |
decreases response to substance |
ISO |
AIFM3 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr11:83,504,859...83,523,630
Ensembl chr11:83,504,861...83,521,248
|
|
G |
Akap13 |
A-kinase anchoring protein 13 |
decreases response to substance |
ISO |
AKAP13 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 1:129,313,183...129,619,647
Ensembl chr 1:129,314,402...129,619,646
|
|
G |
Akap8 |
A-kinase anchoring protein 8 |
increases expression |
ISO |
Camptothecin results in increased expression of AKAP8 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 7:11,316,224...11,332,523
Ensembl chr 7:11,316,228...11,332,399
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation multiple interactions increases phosphorylation |
ISO |
Camptothecin affects the phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Camptothecin results in increased phosphorylation of AKT1 protein]; Camptothecin results in decreased expression of and results in decreased phosphorylation of AKT1 protein; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in decreased phosphorylation of AKT1 protein]; Nicotine affects the reaction [Camptothecin affects the phosphorylation of AKT1 protein]; Wortmannin inhibits the reaction [Camptothecin results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:24095863 PMID:30851366 PMID:36394428 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
affects binding multiple interactions |
ISO |
Camptothecin analog binds to ALB protein; Camptothecin binds to ALB protein CTSB protein results in increased cleavage of [Camptothecin analog binds to ALB protein] |
CTD |
PMID:10803926 PMID:17378599 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alms1 |
ALMS1, centrosome and basal body associated protein |
decreases methylation |
ISO |
Camptothecin results in decreased methylation of ALMS1 gene |
CTD |
PMID:30720231 |
|
NCBI chr 4:118,125,581...118,226,005
Ensembl chr 4:118,125,607...118,226,005
|
|
G |
Anxa4 |
annexin A4 |
increases expression |
ISO |
Camptothecin results in increased expression of ANXA4 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
increases methylation |
ISO |
Camptothecin results in increased methylation of APC gene |
CTD |
PMID:30720231 |
|
NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Artn |
artemin |
decreases response to substance |
ISO |
ARTN mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 5:131,458,596...131,470,193
Ensembl chr 5:131,464,756...131,468,025
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions increases expression |
ISO |
Glutathione inhibits the reaction [Camptothecin results in increased expression of ATF4 protein]; MYC protein affects the reaction [Camptothecin results in increased expression of ATF4 protein] |
CTD |
PMID:30266318 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
ATG5 mutant form inhibits the reaction [Camptothecin results in increased degradation of SQSTM1 protein] |
CTD |
PMID:22927544 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions increases expression |
ISO |
Egtazic Acid inhibits the reaction [Camptothecin results in increased expression of ATG7 protein]; EIF2S1 protein affects the reaction [Camptothecin results in increased expression of ATG7 protein]; staurosporine aglycone inhibits the reaction [Camptothecin results in increased expression of ATG7 protein] |
CTD |
PMID:30266318 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atm |
ATM serine/threonine kinase |
decreases expression multiple interactions increases expression increases activity |
ISO EXP |
Camptothecin results in decreased expression of ATM mRNA Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of ATM protein modified form]; ESR1 promotes the reaction [Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of ATM protein modified form]] camptothecin increases kinase activity in rat cerebellar granule neurons |
CTD RGD |
PMID:24792648 PMID:30720231 PMID:19151707 |
RGD:10053571 |
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atr |
ATR serine/threonine kinase |
decreases response to substance multiple interactions increases phosphorylation |
ISO |
ATR mRNA results in decreased susceptibility to Camptothecin; ATR protein results in decreased susceptibility to Camptothecin 3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide inhibits the reaction [Camptothecin results in increased phosphorylation of ATR protein] |
CTD |
PMID:25269479 PMID:30555576 |
|
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions decreases expression |
ISO |
Folic Acid inhibits the reaction [Camptothecin results in decreased expression of BAK1 mRNA] |
CTD |
PMID:30581319 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases activity increases expression decreases expression |
ISO EXP |
[Camptothecin co-treated with 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole] results in decreased expression of BAX protein; Camptothecin affects the cleavage of and results in decreased expression of BAX protein; Folic Acid inhibits the reaction [Camptothecin results in decreased expression of BAX mRNA] Camptothecin results in increased activity of BAX protein Camptothecin results in increased expression of BAX protein pifithrin inhibits the reaction [Camptothecin results in increased expression of BAX protein] Camptothecin results in decreased expression of BAX mRNA; Camptothecin results in decreased expression of BAX protein |
CTD |
PMID:11279278 PMID:15665116 PMID:17555331 PMID:19481069 PMID:30581319 PMID:30885713 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
affects response to substance |
ISO |
BBC3 protein affects the susceptibility to Camptothecin |
CTD |
PMID:20477944 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases response to substance decreases expression increases expression |
ISO |
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin results in decreased expression of BCL2 protein]; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in decreased expression of BCL2 protein]; Folic Acid inhibits the reaction [Camptothecin results in decreased expression of BCL2 mRNA] BCL2 results in decreased susceptibility to Camptothecin Camptothecin results in decreased expression of BCL2 mRNA; Camptothecin results in decreased expression of BCL2 protein Camptothecin results in increased expression of BCL2 mRNA Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein] |
CTD |
PMID:9664115 PMID:10692111 PMID:10896673 PMID:19481069 PMID:24726431 PMID:25449198 PMID:30581319 PMID:36394428 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases response to substance decreases expression increases expression multiple interactions |
EXP ISO |
BCL2L1 gene mutant form results in decreased susceptibility to Camptothecin Camptothecin results in decreased expression of BCL2L1 protein alternative form Camptothecin results in increased expression of BCL2L1 protein Dexamethasone inhibits the reaction [Camptothecin results in decreased expression of BCL2L1 protein alternative form]; Mifepristone affects the reaction [Dexamethasone inhibits the reaction [Camptothecin results in decreased expression of BCL2L1 protein alternative form]]; Naphthoquinones analog promotes the reaction [Camptothecin results in increased expression of BCL2L1 protein] BCL2L1 mRNA results in decreased susceptibility to Camptothecin Folic Acid inhibits the reaction [Camptothecin results in decreased expression of BCL2L1 mRNA] |
CTD |
PMID:10970895 PMID:19339209 PMID:19497415 PMID:25269479 PMID:30581319 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
ISO |
[Diethylhexyl Phthalate co-treated with Camptothecin] results in decreased expression of BECN1 protein; Egtazic Acid inhibits the reaction [Camptothecin results in increased expression of BECN1 protein]; EIF2S1 protein affects the reaction [Camptothecin results in increased expression of BECN1 protein]; staurosporine aglycone inhibits the reaction [Camptothecin results in increased expression of BECN1 protein] |
CTD |
PMID:30266318 PMID:36394428 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Camptothecin co-treated with 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole] results in increased cleavage of and results in decreased expression of BID protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of BID protein; Camptothecin results in increased cleavage of and results in decreased expression of BID protein |
CTD |
PMID:19481069 PMID:19633536 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions increases expression decreases expression |
ISO |
[Butyrates co-treated with Camptothecin] results in decreased expression of BIRC5 protein; [Folic Acid co-treated with Camptothecin] results in decreased expression of BIRC5 mRNA Camptothecin results in increased expression of BIRC5 mRNA Camptothecin results in decreased expression of BIRC5 mRNA Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein] |
CTD |
PMID:16061681 PMID:24726431 PMID:25449198 PMID:30581319 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bnip1 |
BCL2 interacting protein 1 |
increases expression |
ISO |
Camptothecin results in increased expression of BNIP1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr10:16,386,876...16,399,124
Ensembl chr10:16,386,841...16,399,157
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
decreases expression decreases response to substance |
ISO |
Camptothecin results in decreased expression of BRCA1 mRNA BRCA1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:10344722 PMID:25269479 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
decreases expression |
ISO |
Camptothecin results in decreased expression of BRCA2 mRNA |
CTD |
PMID:10344722 |
|
NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
ISO |
Camptothecin results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 1:205,731,828...205,743,430
Ensembl chr 1:205,733,872...205,743,421
|
|
G |
Cab39 |
calcium binding protein 39 |
decreases expression |
ISO |
Camptothecin results in decreased expression of CAB39 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:86,463,095...86,524,545
Ensembl chr 9:86,463,095...86,524,544
|
|
G |
Casp2 |
caspase 2 |
increases splicing increases expression |
ISO |
Camptothecin results in increased splicing of CASP2 mRNA Camptothecin results in increased expression of CASP2 mRNA alternative form |
CTD |
PMID:14757846 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage |
ISO EXP |
15-deoxyprostaglandin J2 promotes the reaction [Camptothecin results in increased activity of CASP3 protein]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin results in increased activity of CASP3 protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [Camptothecin results in increased activity of CASP3 protein]; [Camptothecin co-treated with FAS protein] results in increased activity of CASP3 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP3 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Camptothecin results in increased cleavage of CASP3 protein]; Camptothecin promotes the reaction [15-deoxyprostaglandin J2 results in increased activity of CASP3 protein]; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased cleavage of CASP3 protein]; palbociclib inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; SMN1 mRNA affects the reaction [Camptothecin results in increased activity of CASP3 protein]; THBS1 protein inhibits the reaction [Camptothecin results in increased activity of CASP3 protein] Cadmium Chloride inhibits the reaction [Camptothecin results in increased cleavage of CASP3 protein]; Cadmium inhibits the reaction [Camptothecin results in increased cleavage of CASP3 protein]; Dexamethasone inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; Naphthoquinones analog inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; Tetrachlorodibenzodioxin promotes the reaction [Camptothecin results in increased cleavage of CASP3 protein] |
CTD |
PMID:10896673 PMID:15862279 PMID:15958570 PMID:16263807 PMID:16273314 PMID:16756956 PMID:16962673 PMID:18506790 PMID:19339209 PMID:19481069 PMID:19497415 PMID:19633536 PMID:21683069 PMID:22302033 PMID:24726431 PMID:24792648 PMID:25412314 PMID:25592883 PMID:25843524 PMID:29384525 PMID:30720231 PMID:33248029 PMID:34635930 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity decreases expression |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Camptothecin results in increased activity of CASP7 protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [Camptothecin results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Camptothecin results in increased activity of CASP7 protein] Camptothecin results in decreased expression of CASP7 mRNA |
CTD |
PMID:22302033 PMID:24726431 PMID:30581319 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions affects cleavage increases activity increases expression decreases expression |
ISO EXP |
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Camptothecin results in increased activity of CASP8 protein]; [Camptothecin co-treated with FAS protein] results in increased activity of CASP8 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP8 protein; Lithium inhibits the reaction [Camptothecin results in increased activity of CASP8 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CASP8 protein] Camptothecin affects the cleavage of CASP8 protein Naphthoquinones analog inhibits the reaction [Camptothecin results in increased activity of CASP8 protein] Camptothecin results in decreased expression of CASP8 mRNA |
CTD |
PMID:10896673 PMID:15475000 PMID:15958570 PMID:19497415 PMID:19633536 PMID:30581319 PMID:30885713 PMID:34635930 More...
|
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity increases cleavage increases expression decreases expression |
ISO EXP |
[Camptothecin co-treated with FAS protein] results in increased activity of CASP9 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP9 protein; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CASP9 protein] benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Camptothecin results in increased cleavage of CASP9 protein]; Cadmium Chloride inhibits the reaction [Camptothecin results in increased activity of CASP9 protein]; Cadmium inhibits the reaction [Camptothecin results in increased activity of CASP9 protein]; Naphthoquinones analog inhibits the reaction [Camptothecin results in increased activity of CASP9 protein] Camptothecin results in decreased expression of CASP9 mRNA |
CTD |
PMID:10896673 PMID:15958570 PMID:16263807 PMID:19497415 PMID:19633536 PMID:24823293 PMID:30581319 PMID:30885713 PMID:34635930 More...
|
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cav1 |
caveolin 1 |
decreases methylation |
ISO |
Camptothecin results in decreased methylation of CAV1 gene |
CTD |
PMID:30720231 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Camptothecin results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Camptothecin results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
ISO |
Camptothecin results in decreased expression of CCL5 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
[Folic Acid co-treated with Camptothecin] results in decreased expression of CCNA2 mRNA Camptothecin results in decreased expression of CCNA2 mRNA |
CTD |
PMID:30581319 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions increases expression decreases expression |
ISO |
[Butyrates co-treated with Camptothecin] results in decreased expression of CCNB1 protein; CDKN1A protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein] Camptothecin results in decreased expression of CCNB1 protein |
CTD |
PMID:16061681 PMID:23376119 PMID:30851366 PMID:30885713 PMID:31255635 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
affects localization |
ISO |
Camptothecin affects the localization of CCND1 protein |
CTD |
PMID:14647467 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO |
Camptothecin results in increased expression of CCNE1 protein |
CTD |
PMID:30851366 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
Camptothecin promotes the reaction [MAD2L1 protein binds to CDC20 protein] |
CTD |
PMID:30885713 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
Camptothecin results in increased expression of and results in increased activity of CDK1 protein; CDKN1A protein affects the reaction [Camptothecin results in increased activity of CDK1 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of and results in increased activity of CDK1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of CDK1 protein] |
CTD |
PMID:30885713 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions increases activity |
ISO EXP |
Camptothecin results in increased phosphorylation of and results in decreased activity of CDK2 protein camptothecin increases kinase activity in rat cerebellar granule neurons |
CTD RGD |
PMID:15141020 PMID:19151707 |
RGD:10053571 |
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
increases activity |
EXP |
camptothecin increases kinase activity in rat cerebellar granule neurons |
RGD |
PMID:19151707 |
RGD:10053571 |
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
increases expression |
ISO |
Camptothecin results in increased expression of CDK5R1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
increases activity |
EXP |
camptothecin increases kinase activity in rat cerebellar granule neurons |
RGD |
PMID:19151707 |
RGD:10053571 |
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
Aspirin inhibits the reaction [Camptothecin results in increased expression of CDKN1A protein]; Camptothecin results in increased expression of and results in increased phosphorylation of CDKN1A protein; CDKN1A protein affects the reaction [Camptothecin results in increased activity of CDK1 protein]; CDKN1A protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein]; CDKN1A protein affects the reaction [Camptothecin results in increased expression of MAD2L1 protein] Camptothecin results in increased expression of CDKN1A mRNA; Camptothecin results in increased expression of CDKN1A protein |
CTD |
PMID:9673414 PMID:17555331 PMID:19212664 PMID:24211769 PMID:30022047 PMID:30851366 PMID:30885713 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
increases expression |
ISO |
Camptothecin results in increased expression of CEACAM1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Cebpz |
CCAAT/enhancer binding protein zeta |
decreases expression |
ISO |
Camptothecin results in decreased expression of CEBPZ mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:16,119,871...16,137,600
Ensembl chr 6:16,119,872...16,137,600
|
|
G |
Cep85l |
centrosomal protein 85-like |
increases methylation |
ISO |
Camptothecin results in increased methylation of CEP85L gene |
CTD |
PMID:30720231 |
|
NCBI chr20:32,568,417...32,739,449
Ensembl chr20:32,572,741...32,739,516
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein] |
CTD |
PMID:25449198 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions increases phosphorylation increases expression decreases response to substance |
ISO |
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Camptothecin results in increased phosphorylation of CHEK1 protein]; 7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased expression of CHEK1 mRNA]; 7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased phosphorylation of CHEK1 protein]; Caffeine inhibits the reaction [Camptothecin results in increased expression of CHEK1 mRNA]; Caffeine inhibits the reaction [Camptothecin results in increased phosphorylation of CHEK1 protein] 3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide inhibits the reaction [Camptothecin results in increased expression of CHEK1 protein modified form]; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of CHEK1 protein modified form] CHEK1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:21646468 PMID:22403396 PMID:25269479 PMID:30555576 PMID:30720231 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases expression increases phosphorylation multiple interactions |
ISO |
Camptothecin results in increased expression of CHEK2 protein modified form Camptothecin results in increased phosphorylation of CHEK2 protein Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of CHEK2 protein modified form] |
CTD |
PMID:21646468 PMID:25269479 PMID:25977998 PMID:30720231 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Clptm1l |
CLPTM1-like |
increases response to substance |
ISO |
CLPTM1L mutant form results in increased susceptibility to Camptothecin |
CTD |
PMID:22675468 |
|
NCBI chr 1:29,667,545...29,683,530
Ensembl chr 1:29,667,545...29,683,530
|
|
G |
Coil |
coilin |
increases expression |
ISO |
Camptothecin results in increased expression of COIL mRNA |
CTD |
PMID:33770205 |
|
NCBI chr10:73,789,077...73,810,378
Ensembl chr10:73,789,488...73,810,393
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
EXP |
Camptothecin inhibits the reaction [RELA protein binds to CREBBP protein]; Camptothecin promotes the reaction [TP53 protein binds to CREBBP protein]; pifithrin inhibits the reaction [Camptothecin inhibits the reaction [RELA protein binds to CREBBP protein]]; pifithrin inhibits the reaction [Camptothecin promotes the reaction [TP53 protein binds to CREBBP protein]] |
CTD |
PMID:13679428 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crx |
cone-rod homeobox |
decreases response to substance |
ISO |
CRX mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 1:76,539,812...76,553,694
Ensembl chr 1:76,540,141...76,545,818
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
CTSB protein results in increased cleavage of [Camptothecin analog binds to ALB protein] |
CTD |
PMID:17378599 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions affects localization |
ISO |
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin affects the localization of CYCS protein] |
CTD |
PMID:19481069 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
decreases response to substance |
ISO |
CYP26B1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases expression multiple interactions |
ISO |
Camptothecin results in decreased expression of CYP2B6 mRNA Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA] |
CTD |
PMID:29356861 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases expression multiple interactions |
ISO |
Camptothecin results in decreased expression of CYP2C8 mRNA Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA] |
CTD |
PMID:29356861 |
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:29356861 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression decreases expression |
ISO |
Folic Acid inhibits the reaction [Camptothecin results in decreased expression of DDIT3 mRNA]; MYC protein affects the reaction [Camptothecin results in increased expression of DDIT3 protein] |
CTD |
PMID:30266318 PMID:30581319 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dgkz |
diacylglycerol kinase zeta |
decreases response to substance |
ISO |
DGKZ mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 3:77,904,149...77,946,114
Ensembl chr 3:77,904,150...77,946,099
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
multiple interactions decreases expression decreases activity |
ISO |
Camptothecin inhibits the reaction [Fluorouracil results in increased expression of DPYD mRNA] Camptothecin results in decreased expression of DPYD mRNA Camptothecin results in decreased activity of DPYD protein |
CTD |
PMID:16568373 |
|
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
|
|
G |
Dtwd1 |
DTW domain containing 1 |
increases expression |
ISO |
Camptothecin results in increased expression of DTWD1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:113,392,402...113,409,322
Ensembl chr 3:113,392,457...113,408,105
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions increases expression |
ISO |
7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased expression of E2F1 mRNA]; Caffeine inhibits the reaction [Camptothecin results in increased expression of E2F1 mRNA]; E2F1 protein promotes the reaction [Camptothecin results in increased expression of RRM2 protein] |
CTD |
PMID:22403396 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f8 |
E2F transcription factor 8 |
increases expression |
ISO |
Camptothecin results in increased expression of E2F8 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Ei24 |
EI24, autophagy associated transmembrane protein |
increases expression |
ISO |
Camptothecin results in increased expression of EI24 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 8:36,494,289...36,510,653
Ensembl chr 8:36,494,289...36,510,571
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases phosphorylation |
ISO |
Glutathione inhibits the reaction [Camptothecin results in increased phosphorylation of EIF2AK3 protein]; MYC protein affects the reaction [Camptothecin results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:30266318 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO EXP |
Camptothecin results in increased phosphorylation of EIF2S1 protein EIF2S1 protein affects the reaction [Camptothecin results in increased expression of ATG7 protein]; EIF2S1 protein affects the reaction [Camptothecin results in increased expression of BECN1 protein]; Glutathione inhibits the reaction [Camptothecin results in increased phosphorylation of EIF2S1 protein]; MYC protein affects the reaction [Camptothecin results in increased phosphorylation of EIF2S1 protein] [Camptothecin co-treated with GW 506033X] results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:19046382 PMID:30266318 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Ep300 |
E1A binding protein p300 |
decreases expression |
ISO |
Camptothecin results in decreased expression of EP300 mRNA; Camptothecin results in decreased expression of EP300 protein |
CTD |
PMID:10344722 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epm2aip1 |
EPM2A interacting protein 1 |
increases expression |
ISO |
Camptothecin results in increased expression of EPM2AIP1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 8:111,233,871...111,241,219
Ensembl chr 8:111,233,826...111,241,871
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
multiple interactions decreases expression |
ISO |
ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] Camptothecin results in decreased expression of ERCC1 mRNA |
CTD |
PMID:21227924 PMID:24792648 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Ercc4 |
ERCC excision repair 4, endonuclease catalytic subunit |
multiple interactions decreases response to substance |
ISO |
ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] ERCC4 protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:21227924 |
|
NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of ESR1 protein; ESR1 promotes the reaction [Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of ATM protein modified form]]; ESR1 promotes the reaction [Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]] |
CTD |
PMID:25752796 PMID:30720231 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of ESR2 protein |
CTD |
PMID:25752796 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Camptothecin results in increased expression of and affects the localization of FAS protein]; [Camptothecin co-treated with FAS protein] results in decreased expression of XIAP protein; [Camptothecin co-treated with FAS protein] results in increased activity of CASP3 protein; [Camptothecin co-treated with FAS protein] results in increased activity of CASP8 protein; [Camptothecin co-treated with FAS protein] results in increased activity of CASP9 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of BID protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP3 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP8 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP9 protein; Camptothecin results in increased expression of and affects the localization of FAS protein; Lithium inhibits the reaction [Camptothecin results in increased expression of and affects the localization of FAS protein] |
CTD |
PMID:15475000 PMID:15958570 PMID:19633536 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fdxr |
ferredoxin reductase |
increases expression |
ISO |
Camptothecin results in increased expression of FDXR mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658
|
|
G |
Fxn |
frataxin |
increases expression |
ISO |
Camptothecin results in increased expression of FXN protein |
CTD |
PMID:23418481 |
|
NCBI chr 1:221,874,007...221,897,543
Ensembl chr 1:221,872,420...221,897,540
|
|
G |
Fzd1 |
frizzled class receptor 1 |
decreases methylation |
ISO |
Camptothecin results in decreased methylation of FZD1 gene |
CTD |
PMID:30720231 |
|
NCBI chr 4:29,310,303...29,314,701
Ensembl chr 4:29,310,091...29,312,643 Ensembl chr 4:29,310,091...29,312,643
|
|
G |
Fzd8 |
frizzled class receptor 8 |
decreases methylation |
ISO |
Camptothecin results in decreased methylation of FZD8 gene |
CTD |
PMID:30720231 |
|
NCBI chr17:57,312,924...57,320,551
Ensembl chr17:57,314,450...57,320,650
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
decreases expression multiple interactions |
ISO |
Camptothecin results in decreased expression of GADD45A mRNA Folic Acid inhibits the reaction [Camptothecin results in decreased expression of GADD45A mRNA] |
CTD |
PMID:24792648 PMID:30581319 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
increases expression |
ISO |
Camptothecin results in increased expression of GADD45G mRNA |
CTD |
PMID:24792648 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Git2 |
GIT ArfGAP 2 |
decreases response to substance |
ISO |
GIT2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr12:41,829,717...41,872,621
Ensembl chr12:41,829,730...41,871,097
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
decreases response to substance |
ISO |
GPX4 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression decreases response to substance |
ISO |
Camptothecin results in increased expression of GSTP1 protein GSTP1 protein polymorphism results in decreased susceptibility to Camptothecin; GSTP1 protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:14732228 PMID:15500952 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression increases phosphorylation |
ISO EXP |
3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; [Aminacrine results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; [MIR138-1 results in decreased expression of H2AX] which results in increased susceptibility to Camptothecin; [Propyl Gallate results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ESR1 promotes the reaction [Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]]; H2AX gene mutant form inhibits the reaction [MIR138-1 results in increased susceptibility to Camptothecin]; palbociclib inhibits the reaction [Camptothecin results in increased expression of H2AX protein]; PPP2R2A protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; PPP2R5C protein promotes the reaction [Camptothecin results in increased expression of H2AX protein modified form]; PPP2R5E protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; TDP1 protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein]; TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein] Camptothecin results in increased expression of H2AX protein; Camptothecin results in increased expression of H2AX protein modified form Camptothecin results in increased phosphorylation of H2AX protein |
CTD |
PMID:17875725 PMID:21227924 PMID:21646468 PMID:21693595 PMID:22302033 PMID:25269479 PMID:25772433 PMID:26928355 PMID:30720231 PMID:32482060 More...
|
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
decreases expression |
ISO |
Camptothecin results in decreased expression of HAMP mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hemk1 |
HemK methyltransferase family member 1 |
decreases response to substance |
ISO |
HEMK1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 8:107,999,658...108,010,732
Ensembl chr 8:107,999,644...108,010,256
|
|
G |
Hnrnpc |
heterogeneous nuclear ribonucleoprotein C |
multiple interactions |
ISO |
[HNRNPC protein binds to HNRNPC protein alternative form] which results in decreased susceptibility to Camptothecin |
CTD |
PMID:16960656 |
|
NCBI chr15:24,779,593...24,809,213
Ensembl chr15:24,779,450...24,809,183
|
|
G |
Hoxa1 |
homeobox A1 |
decreases response to substance multiple interactions |
ISO |
HOXA1 mRNA results in decreased susceptibility to Camptothecin Camptothecin inhibits the reaction [Vitamin A results in increased expression of HOXA1] |
CTD |
PMID:25269479 PMID:26820057 |
|
NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Ibsp |
integrin-binding sialoprotein |
decreases response to substance |
ISO |
IBSP mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr14:5,439,825...5,452,570
Ensembl chr14:5,439,829...5,452,693
|
|
G |
Il1b |
interleukin 1 beta |
decreases response to substance |
ISO |
IL1B protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:16356833 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression |
ISO |
Camptothecin results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Jarid2 |
jumonji and AT-rich interaction domain containing 2 |
decreases expression |
ISO |
Camptothecin results in decreased expression of JARID2 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr17:19,777,487...19,957,696
Ensembl chr17:19,777,266...19,955,690
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression increases phosphorylation multiple interactions |
ISO EXP |
Camptothecin results in increased expression of JUN protein Camptothecin results in increased phosphorylation of JUN protein Glutathione inhibits the reaction [Camptothecin results in increased phosphorylation of JUN protein]; MAPK8 protein affects the reaction [Camptothecin results in increased phosphorylation of JUN protein] |
CTD |
PMID:9751194 PMID:15585644 PMID:30266318 PMID:30885713 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnk2 |
potassium two pore domain channel subfamily K member 2 |
decreases response to substance |
ISO |
KCNK2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr13:100,766,101...100,963,435
Ensembl chr13:100,766,113...100,963,435
|
|
G |
Klhl42 |
kelch-like family, member 42 |
increases expression |
ISO |
Camptothecin results in increased expression of KLHL42 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 4:179,999,655...180,027,283
Ensembl chr 4:180,004,580...180,027,283
|
|
G |
Lgals1 |
galectin 1 |
decreases expression |
ISO |
Camptothecin results in decreased expression of LGALS1 mRNA; Camptothecin results in decreased expression of LGALS1 protein |
CTD |
PMID:19483324 |
|
NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345
|
|
G |
Lrch4 |
leucine rich repeats and calponin homology domain containing 4 |
decreases response to substance |
ISO |
LRCH4 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr12:19,057,582...19,072,573
Ensembl chr12:19,057,587...19,068,577
|
|
G |
Mad2l1 |
mitotic arrest deficient 2 like 1 |
multiple interactions increases expression |
ISO |
Camptothecin promotes the reaction [MAD2L1 protein binds to CDC20 protein]; CDKN1A protein affects the reaction [Camptothecin results in increased expression of MAD2L1 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of and results in increased activity of CDK1 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CASP8 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CASP9 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of MAD2L1 protein] Camptothecin results in increased expression of MAD2L1 mRNA; Camptothecin results in increased expression of MAD2L1 protein |
CTD |
PMID:30885713 |
|
NCBI chr 4:95,906,692...95,918,885
Ensembl chr 4:95,906,817...95,913,470
|
|
G |
Map2k3 |
mitogen activated protein kinase kinase 3 |
increases expression |
ISO |
Camptothecin results in increased expression of MAP2K3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases expression |
ISO |
Camptothecin results in decreased expression of MAP3K5 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
decreases response to substance |
ISO |
MAP3K7 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Camptothecin co-treated with Nicotine] results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:24095863 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Camptothecin co-treated with Nicotine] results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:24095863 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions |
ISO |
Camptothecin results in increased phosphorylation of MAPK8 protein MAPK8 protein affects the reaction [Camptothecin results in increased activity of SP1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of CDK1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of MAD2L1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased phosphorylation of JUN protein] |
CTD |
PMID:30885713 PMID:31255635 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation |
ISO |
Camptothecin results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:15585644 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
ISO |
Camptothecin results in decreased expression of MAPT mRNA; Camptothecin results in decreased expression of MAPT protein |
CTD |
PMID:16930453 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mdc1 |
mediator of DNA damage checkpoint 1 |
multiple interactions |
ISO |
[Aminacrine results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; [Propyl Gallate results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; Aminacrine inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; Camptothecin results in increased activity of and affects the localization of MDC1 protein; Propyl Gallate inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein] |
CTD |
PMID:26928355 |
|
NCBI chr20:2,893,693...2,912,394
Ensembl chr20:2,895,505...2,910,240
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
Camptothecin results in increased expression of MDM2 protein |
CTD |
PMID:17555331 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases expression |
ISO |
Camptothecin results in decreased expression of MGMT mRNA |
CTD |
PMID:18492797 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mir138-1 |
microRNA 138-1 |
multiple interactions increases response to substance |
ISO |
[MIR138-1 results in decreased expression of H2AX] which results in increased susceptibility to Camptothecin; H2AX gene mutant form inhibits the reaction [MIR138-1 results in increased susceptibility to Camptothecin] |
CTD |
PMID:21693595 |
|
NCBI chr 8:122,300,966...122,301,064
Ensembl chr 8:122,300,966...122,301,064
|
|
G |
Mir145 |
microRNA 145 |
increases expression decreases expression |
ISO |
Camptothecin results in increased expression of MIR145 mRNA Camptothecin results in decreased expression of MIR145 mRNA |
CTD |
PMID:24726431 |
|
NCBI chr18:55,099,640...55,099,727
Ensembl chr18:55,099,640...55,099,727
|
|
G |
Mir34a |
microRNA 34a |
increases expression |
ISO |
Camptothecin results in increased expression of MIR34A mRNA |
CTD |
PMID:24726431 |
|
NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases response to substance decreases methylation |
ISO |
MMP9 mRNA results in decreased susceptibility to Camptothecin Camptothecin results in decreased methylation of MMP9 gene |
CTD |
PMID:25269479 PMID:30720231 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases expression |
ISO |
Camptothecin results in decreased expression of MRE11 mRNA |
CTD |
PMID:24792648 |
|
NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279
|
|
G |
Mtmr2 |
myotubularin related protein 2 |
decreases response to substance |
ISO |
MTMR2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 8:10,617,993...10,670,724
Ensembl chr 8:10,617,993...10,668,172
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases expression |
ISO |
Camptothecin results in decreased expression of MTOR protein |
CTD |
PMID:31255635 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression affects localization multiple interactions |
ISO |
Camptothecin results in increased expression of MYC mRNA Camptothecin affects the localization of MYC protein Camptothecin results in increased expression of and results in increased activity of MYC protein; MYC protein affects the reaction [Camptothecin results in increased expression of ATF4 protein]; MYC protein affects the reaction [Camptothecin results in increased expression of DDIT3 protein]; MYC protein affects the reaction [Camptothecin results in increased phosphorylation of EIF2AK3 protein]; MYC protein affects the reaction [Camptothecin results in increased phosphorylation of EIF2S1 protein]; TERT protein affects the reaction [Camptothecin results in increased expression of MYC protein] |
CTD |
PMID:30266318 PMID:30851366 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myo1e |
myosin IE |
decreases expression |
ISO |
Camptothecin results in decreased expression of MYO1E mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 8:70,887,934...71,080,180
Ensembl chr 8:70,887,870...71,080,169
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
decreases response to substance |
ISO |
NCAM1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014
|
|
G |
Nck2 |
NCK adaptor protein 2 |
decreases expression |
ISO |
Camptothecin results in decreased expression of NCK2 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:45,713,979...45,840,330
Ensembl chr 9:45,714,883...45,840,307
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]] |
CTD |
PMID:29356861 |
|
NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [NCOR2 protein binds to NR1I2 protein] |
CTD |
PMID:29356861 |
|
NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases activity |
ISO |
NFE2L2 protein affects the reaction [Camptothecin results in increased expression of TERT mRNA] Camptothecin results in increased activity of NFE2L2 protein |
CTD |
PMID:30851366 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Camptothecin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein] |
CTD |
PMID:29356861 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Or1a1b |
olfactory receptor family 1 subfamily A member 1B |
decreases response to substance |
ISO |
OR1A2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr10:59,070,239...59,071,183
Ensembl chr10:59,069,404...59,075,457
|
|
G |
Or7c70 |
olfactory receptor family 7 subfamily C member 70 |
decreases response to substance |
ISO |
OR7C2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 7:10,810,624...10,811,586
Ensembl chr 7:10,799,830...10,813,059
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage decreases response to substance affects response to substance |
ISO EXP |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [Camptothecin results in increased cleavage of PARP1 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; Camptothecin results in increased ADP-ribosylation of and results in increased degradation of PARP1 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Camptothecin results in increased ADP-ribosylation of and results in increased degradation of PARP1 protein]; Nicotine inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; PARP1 protein promotes the reaction [Camptothecin results in increased abundance of Poly Adenosine Diphosphate Ribose]; RBL2 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; THBS1 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; XRCC1 protein affects the reaction [PARP1 protein affects the susceptibility to Camptothecin] [Camptothecin co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased cleavage of PARP1 protein; [veliparib results in decreased activity of PARP1 protein] which results in increased susceptibility to Camptothecin Tetrachlorodibenzodioxin promotes the reaction [Camptothecin results in increased cleavage of PARP1 protein] PARP1 results in decreased susceptibility to Camptothecin |
CTD |
PMID:11741290 PMID:15585644 PMID:16962673 PMID:18506790 PMID:19559722 PMID:22158865 PMID:23376119 PMID:24095863 PMID:24726431 PMID:24792648 PMID:24823293 PMID:25412314 PMID:25449198 PMID:25843524 PMID:27694308 PMID:29384525 PMID:31255635 PMID:35778544 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Plk3 |
polo-like kinase 3 |
increases expression |
ISO |
Camptothecin results in increased expression of PLK3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 5:130,607,142...130,612,317
Ensembl chr 5:130,607,142...130,612,317
|
|
G |
Ppp1r16b |
protein phosphatase 1, regulatory subunit 16B |
decreases response to substance |
ISO |
PPP1R16B mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 3:147,323,652...147,419,658
Ensembl chr 3:147,324,126...147,418,937
|
|
G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
decreases response to substance |
ISO |
PPP1R1B protein alternative form results in decreased susceptibility to Camptothecin; PPP1R1B protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:16061638 |
|
NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
multiple interactions |
ISO |
Camptothecin affects the localization of [PPP2R5E protein binds to PPP2CA protein] |
CTD |
PMID:25772433 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
affects localization decreases response to substance |
ISO |
Camptothecin affects the localization of PPP2R1A protein PPP2R1A mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 PMID:25772433 |
|
NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129
|
|
G |
Ppp2r2a |
protein phosphatase 2, regulatory subunit B, alpha |
multiple interactions decreases response to substance |
ISO |
PPP2R2A protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form] PPP2R2A protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:25772433 |
|
NCBI chr15:41,204,659...41,263,924
Ensembl chr15:41,204,200...41,263,924
|
|
G |
Ppp2r5c |
protein phosphatase 2, regulatory subunit B', gamma |
multiple interactions increases response to substance |
ISO |
PPP2R5C protein promotes the reaction [Camptothecin results in increased expression of H2AX protein modified form] PPP2R5C protein results in increased susceptibility to Camptothecin |
CTD |
PMID:25772433 |
|
NCBI chr 6:129,461,689...129,598,344
Ensembl chr 6:129,461,648...129,598,346
|
|
G |
Ppp2r5e |
protein phosphatase 2 regulatory subunit B', epsilon |
multiple interactions decreases response to substance |
ISO |
Camptothecin affects the localization of [PPP2R5E protein binds to PPP2CA protein]; PPP2R5E protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form] PPP2R5E protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:25772433 |
|
NCBI chr 6:94,168,846...94,317,872
Ensembl chr 6:94,168,846...94,317,872
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
ISO |
Camptothecin results in decreased expression of PRC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Psd3 |
pleckstrin and Sec7 domain containing 3 |
decreases expression |
ISO |
Camptothecin results in decreased expression of PSD3 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr16:21,465,643...22,035,846
Ensembl chr16:21,465,639...22,034,547
|
|
G |
Ptar1 |
protein prenyltransferase alpha subunit repeat containing 1 |
decreases response to substance |
ISO |
PTAR1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 1:221,283,306...221,326,861
Ensembl chr 1:221,283,415...221,327,073
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Camptothecin results in decreased expression of and results in decreased phosphorylation of PTEN protein |
CTD |
PMID:30885713 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptpro |
protein tyrosine phosphatase, receptor type, O |
decreases response to substance |
ISO |
PTPRO mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 4:170,164,071...170,374,790
Ensembl chr 4:170,164,431...170,374,771
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
decreases expression |
ISO |
Camptothecin results in decreased expression of RAD50 mRNA |
CTD |
PMID:24792648 |
|
NCBI chr10:37,809,353...37,861,309
Ensembl chr10:37,808,726...37,861,396
|
|
G |
Rad51 |
RAD51 recombinase |
decreases expression |
ISO |
Camptothecin results in decreased expression of RAD51 mRNA; Camptothecin results in decreased expression of RAD51 protein |
CTD |
PMID:10344722 PMID:24792648 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Rad51c |
RAD51 paralog C |
increases response to substance |
ISO |
RAD51C gene mutant form results in increased susceptibility to Camptothecin |
CTD |
PMID:20400963 |
|
NCBI chr10:72,205,032...72,231,643
Ensembl chr10:72,205,032...72,231,248
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases methylation |
ISO |
Camptothecin results in increased methylation of RARA gene |
CTD |
PMID:30720231 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
increases phosphorylation affects response to substance |
ISO |
Camptothecin results in increased phosphorylation of RB1 protein RB1 protein affects the susceptibility to Camptothecin |
CTD |
PMID:14647467 PMID:14704340 PMID:15064736 PMID:15585644 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
decreases expression |
ISO |
Camptothecin results in decreased expression of RBL1 protein |
CTD |
PMID:15585644 |
|
NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330
|
|
G |
Rbl2 |
RB transcriptional corepressor like 2 |
multiple interactions decreases response to substance |
ISO |
RBL2 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein] RBL2 protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:15585644 |
|
NCBI chr19:15,876,852...15,923,632
Ensembl chr19:15,876,853...15,923,572
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases response to substance multiple interactions |
ISO EXP |
RELA results in increased susceptibility to Camptothecin Camptothecin inhibits the reaction [RELA protein binds to CREBBP protein]; pifithrin inhibits the reaction [Camptothecin inhibits the reaction [RELA protein binds to CREBBP protein]] Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein] Camptothecin results in increased expression of and results in decreased phosphorylation of RELA protein; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in decreased phosphorylation of RELA protein]; Diethylhexyl Phthalate promotes the reaction [Camptothecin results in increased expression of RELA protein] |
CTD |
PMID:13679428 PMID:21737676 PMID:25449198 PMID:36394428 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ret |
ret proto-oncogene |
decreases expression |
EXP |
Camptothecin results in decreased expression of RET protein |
CTD |
PMID:17555550 |
|
NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176
|
|
G |
Rnf31 |
ring finger protein 31 |
decreases response to substance |
ISO |
RNF31 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr15:29,083,047...29,095,328
Ensembl chr15:29,083,631...29,101,915
|
|
G |
Rps6 |
ribosomal protein S6 |
increases expression |
ISO |
Camptothecin results in increased expression of RPS6 protein modified form |
CTD |
PMID:29384525 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
multiple interactions increases expression |
ISO |
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Camptothecin results in increased expression of RRM2 protein]; 7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased expression of RRM2 mRNA]; 7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased expression of RRM2 protein]; Caffeine inhibits the reaction [Camptothecin results in increased expression of RRM2 mRNA]; Caffeine inhibits the reaction [Camptothecin results in increased expression of RRM2 protein]; E2F1 protein promotes the reaction [Camptothecin results in increased expression of RRM2 protein] Camptothecin results in increased expression of RRM2 mRNA; Camptothecin results in increased expression of RRM2 protein |
CTD |
PMID:22403396 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
Rwdd3 |
RWD domain containing 3 |
increases expression |
ISO |
Camptothecin results in increased expression of RWDD3 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 2:209,233,622...209,254,842
Ensembl chr 2:209,233,622...209,248,853
|
|
G |
Sdc1 |
syndecan 1 |
increases expression |
ISO |
Camptothecin results in increased expression of SDC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264
|
|
G |
Sel1l |
SEL1L adaptor subunit of SYVN1 ubiquitin ligase |
decreases response to substance |
ISO |
SEL1L mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 6:110,735,450...110,779,695
Ensembl chr 6:110,735,450...110,779,648
|
|
G |
Sgtb |
small glutamine rich tetratricopeptide repeat co-chaperone beta |
decreases expression |
ISO |
Camptothecin results in decreased expression of SGTB mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 2:35,233,045...35,269,527
Ensembl chr 2:35,233,042...35,269,518
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
ISO |
[SIRT1 mutant form co-treated with Camptothecin] results in increased acetylation of TP53 protein; Camptothecin inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in increased expression of SIRT1 protein] Camptothecin results in decreased expression of SIRT1 protein |
CTD |
PMID:24726431 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc2a12 |
solute carrier family 2 member 12 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SLC2A12 gene |
CTD |
PMID:30720231 |
|
NCBI chr 1:22,803,068...22,862,204
Ensembl chr 1:22,804,418...22,860,971
|
|
G |
Smn1 |
survival of motor neuron 1, telomeric |
multiple interactions increases response to substance |
ISO |
SMN1 mRNA affects the reaction [Camptothecin results in increased activity of CASP3 protein] SMN1 protein results in increased susceptibility to Camptothecin |
CTD |
PMID:15862279 |
|
NCBI chr 2:31,490,018...31,501,065
Ensembl chr 2:31,490,015...31,501,060
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3 |
increases expression |
ISO |
Camptothecin results in increased expression of SMPD3 mRNA |
CTD |
PMID:19698806 |
|
NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression multiple interactions |
ISO |
Camptothecin results in increased expression of SOD1 protein Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of SOD1 protein] |
CTD |
PMID:30720231 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO |
Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of SOD2 protein] |
CTD |
PMID:30720231 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox11 |
SRY-box transcription factor 11 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX11 gene |
CTD |
PMID:30720231 |
|
NCBI chr 6:44,008,333...44,010,354
Ensembl chr 6:44,008,340...44,010,354
|
|
G |
Sox12 |
SRY-box transcription factor 12 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX12 gene |
CTD |
PMID:30720231 |
|
NCBI chr 3:140,859,499...140,860,518
Ensembl chr 3:140,856,579...140,860,975
|
|
G |
Sox17 |
SRY-box transcription factor 17 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX17 gene |
CTD |
PMID:30720231 |
|
NCBI chr 5:15,016,660...15,022,228
Ensembl chr 5:15,016,731...15,022,228
|
|
G |
Sox3 |
SRY-box transcription factor 3 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX3 gene |
CTD |
PMID:30720231 |
|
NCBI chr X:139,308,608...139,310,687
Ensembl chr X:139,309,329...139,310,678
|
|
G |
Sox4 |
SRY-box transcription factor 4 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX4 gene |
CTD |
PMID:30720231 |
|
NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665
|
|
G |
Sox8 |
SRY-box transcription factor 8 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX8 gene |
CTD |
PMID:30720231 |
|
NCBI chr10:14,584,829...14,589,818
Ensembl chr10:14,584,829...14,589,818
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions increases activity increases expression |
ISO |
Acetylcysteine inhibits the reaction [Camptothecin results in increased expression of SP1 mRNA]; Camptothecin results in increased activity of and affects the localization of SP1 protein; Camptothecin results in increased expression of and results in increased activity of SP1 protein; MAPK8 protein affects the reaction [Camptothecin results in increased activity of SP1 protein]; mithramycin A inhibits the reaction [Camptothecin results in increased activity of SP1 protein]; TERT protein affects the reaction [Camptothecin results in increased expression of SP1 protein] |
CTD |
PMID:11261509 PMID:30851366 PMID:30885713 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Sp3 |
Sp3 transcription factor |
increases activity multiple interactions |
ISO |
Camptothecin results in increased activity of SP3 protein mithramycin A inhibits the reaction [Camptothecin results in increased activity of SP3 protein] |
CTD |
PMID:11261509 |
|
NCBI chr 3:57,811,855...57,857,150
Ensembl chr 3:57,812,075...57,860,342
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases degradation |
ISO |
ATG5 mutant form inhibits the reaction [Camptothecin results in increased degradation of SQSTM1 protein]; Camptothecin inhibits the reaction [Cannabidiol results in increased expression of SQSTM1 mRNA] |
CTD |
PMID:22927544 PMID:34302491 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srgap3 |
SLIT-ROBO Rho GTPase activating protein 3 |
decreases expression |
ISO |
Camptothecin results in decreased expression of SRGAP3 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 4:145,839,369...146,070,556
Ensembl chr 4:145,840,078...146,070,575
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
ISO |
Camptothecin results in increased expression of SRXN1 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Stambpl1 |
STAM binding protein-like 1 |
increases methylation |
ISO |
Camptothecin results in increased methylation of STAMBPL1 gene |
CTD |
PMID:30720231 |
|
NCBI chr 1:231,699,620...231,745,034
Ensembl chr 1:231,699,995...231,745,032
|
|
G |
Styxl1 |
serine/threonine/tyrosine interacting-like 1 |
decreases response to substance |
ISO |
STYXL1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr12:20,907,410...20,940,232
Ensembl chr12:20,907,435...20,939,752
|
|
G |
Suv39h1 |
SUV39H1 histone lysine methyltransferase |
increases expression |
ISO |
Camptothecin results in increased expression of SUV39H1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr X:14,421,028...14,433,993
Ensembl chr X:14,421,109...14,433,982
|
|
G |
Suv39h1-ps1 |
SUV39H1 histone lysine methyltransferase, pseudogene 1 |
increases expression |
ISO |
Camptothecin results in increased expression of SUV39H1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr X:141,792,589...141,795,257
|
|
G |
Tab2 |
TGF-beta activated kinase 1/MAP3K7 binding protein 2 |
decreases response to substance |
ISO |
TAB2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 1:2,375,026...2,425,115
Ensembl chr 1:2,375,490...2,424,756
|
|
G |
Tap1 |
transporter 1, ATP binding cassette subfamily B member |
increases expression |
ISO |
Camptothecin results in increased expression of TAP1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901
|
|
G |
Tax1bp3 |
Tax1 binding protein 3 |
increases expression |
ISO |
Camptothecin results in increased expression of TAX1BP3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:57,795,845...57,800,363
Ensembl chr10:57,795,382...57,800,363
|
|
G |
Tbc1d16 |
TBC1 domain family, member 16 |
decreases expression |
ISO |
Camptothecin results in decreased expression of TBC1D16 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr10:104,400,963...104,486,698
Ensembl chr10:104,402,398...104,486,670
|
|
G |
Tdp1 |
tyrosyl-DNA phosphodiesterase 1 |
multiple interactions |
ISO |
TDP1 protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein]; TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] |
CTD |
PMID:21227924 |
|
NCBI chr 6:119,163,192...119,231,029
Ensembl chr 6:119,163,166...119,231,021
|
|
G |
Tert |
telomerase reverse transcriptase |
increases expression multiple interactions |
ISO |
Camptothecin results in increased expression of TERT mRNA 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Camptothecin results in increased phosphorylation of TERT protein]; Acetylcysteine inhibits the reaction [Camptothecin results in increased expression of TERT protein]; Camptothecin results in increased expression of and results in increased phosphorylation of TERT protein; Glutathione inhibits the reaction [Camptothecin results in increased expression of TERT protein]; NFE2L2 protein affects the reaction [Camptothecin results in increased expression of TERT mRNA]; TERT protein affects the reaction [Camptothecin results in increased expression of MYC protein]; TERT protein affects the reaction [Camptothecin results in increased expression of SP1 protein]; Wortmannin inhibits the reaction [Camptothecin results in increased phosphorylation of TERT protein] |
CTD |
PMID:30851366 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Thbs1 |
thrombospondin 1 |
decreases expression multiple interactions decreases secretion |
ISO |
Camptothecin results in decreased expression of THBS1 mRNA THBS1 protein inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; THBS1 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein] Camptothecin results in decreased secretion of THBS1 protein |
CTD |
PMID:16962673 |
|
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of THRA protein |
CTD |
PMID:25752796 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of THRB protein |
CTD |
PMID:25752796 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Tmem250 |
transmembrane protein 250 |
increases expression |
ISO |
Camptothecin results in increased expression of TMEM250 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:8,962,657...8,966,349
Ensembl chr 3:8,962,657...8,966,349
|
|
G |
Tnfsf9 |
TNF superfamily member 9 |
increases expression |
ISO |
Camptothecin results in increased expression of TNFSF9 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:1,944,017...1,946,351
Ensembl chr 9:1,944,017...1,946,345
|
|
G |
Top1 |
DNA topoisomerase I |
multiple interactions decreases response to substance decreases activity |
ISO EXP |
[Ciprofloxacin co-treated with Camptothecin] results in decreased activity of TOP1 protein; [moxifloxacin co-treated with Camptothecin] results in decreased activity of TOP1 protein TOP1 protein mutant form results in decreased susceptibility to Camptothecin Camptothecin analog results in decreased activity of TOP1 protein; Camptothecin results in decreased activity of TOP1 protein |
CTD |
PMID:12097280 PMID:18191106 PMID:20600288 PMID:21056033 PMID:21227924 PMID:23376119 PMID:34635930 More...
|
|
NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases glutathionylation increases activity increases phosphorylation increases response to substance increases expression decreases acetylation affects response to substance decreases response to substance |
ISO EXP |
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin results in increased expression of TP53 protein]; [SIRT1 mutant form co-treated with Camptothecin] results in increased acetylation of TP53 protein; Acetylcysteine inhibits the reaction [Camptothecin results in increased expression of TP53 protein modified form]; Camptothecin inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in increased acetylation of TP53 protein]; Camptothecin results in increased stability of and results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein; nutlin 3 inhibits the reaction [Camptothecin results in increased expression of TP53 protein]; S-ethyl glutathione inhibits the reaction [Camptothecin results in increased expression of TP53 protein modified form] Camptothecin results in increased glutathionylation of TP53 protein Camptothecin results in increased activity of TP53 protein Camptothecin results in increased phosphorylation of TP53 protein Camptothecin promotes the reaction [TP53 protein binds to CREBBP protein]; pifithrin inhibits the reaction [Camptothecin promotes the reaction [TP53 protein binds to CREBBP protein]]; pifithrin inhibits the reaction [Camptothecin results in increased activity of TP53 protein] TP53 protein results in increased susceptibility to Camptothecin Camptothecin results in decreased acetylation of TP53 protein TRP53 protein affects the susceptibility to Camptothecin TP53 mutant form results in decreased susceptibility to Camptothecin; TP53 protein mutant form results in decreased susceptibility to Camptothecin; TP53 protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:9673414 PMID:10692111 PMID:11279278 PMID:11741290 PMID:12082016 PMID:13679428 PMID:17555331 PMID:19481069 PMID:20477944 PMID:20978201 PMID:23285096 PMID:24726431 PMID:25269479 PMID:26657896 More...
|
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53i3 |
tumor protein p53 inducible protein 3 |
increases expression |
ISO |
Camptothecin results in increased expression of TP53I3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:27,818,327...27,825,753
|
|
G |
Tp63 |
tumor protein p63 |
decreases expression |
ISO |
Camptothecin results in decreased expression of TP63 protein alternative form |
CTD |
PMID:23376119 |
|
NCBI chr11:74,838,858...75,049,764
Ensembl chr11:74,838,859...75,049,398
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
decreases response to substance |
ISO |
TRAF6 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Trim28 |
tripartite motif-containing 28 |
increases expression |
ISO |
Camptothecin results in increased expression of TRIM28 protein modified form |
CTD |
PMID:25977998 |
|
NCBI chr 1:73,652,441...73,659,388
Ensembl chr 1:73,652,709...73,659,380
|
|
G |
Tsg101 |
tumor susceptibility 101 |
decreases response to substance |
ISO |
TSG101 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 1:97,412,689...97,442,589
Ensembl chr 1:97,410,848...97,442,554
|
|
G |
Tulp4 |
TUB like protein 4 |
decreases expression |
ISO |
Camptothecin results in decreased expression of TULP4 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 1:46,682,416...46,813,167
Ensembl chr 1:46,682,863...46,809,688
|
|
G |
Twf1 |
twinfilin actin-binding protein 1 |
decreases response to substance |
ISO |
TWF1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 7:125,715,938...125,727,834
Ensembl chr 7:125,716,015...125,727,894
|
|
G |
Tyms |
thymidylate synthetase |
increases expression |
ISO |
Camptothecin results in increased expression of TYMS mRNA |
CTD |
PMID:16568373 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
decreases methylation |
ISO |
Camptothecin results in decreased methylation of UGT1A6 gene |
CTD |
PMID:30720231 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Upf1 |
UPF1, RNA helicase and ATPase |
decreases response to substance |
ISO |
UPF1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr16:19,076,594...19,097,365
Ensembl chr16:19,076,322...19,096,568
|
|
G |
Usp5 |
ubiquitin specific peptidase 5 |
decreases response to substance |
ISO |
USP5 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 4:157,619,663...157,634,681
Ensembl chr 4:157,619,643...157,634,711
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression decreases response to substance |
ISO |
Camptothecin results in decreased expression of VEGFA protein VEGFA protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:16356833 PMID:20116850 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions decreases response to substance |
ISO |
[Butyrates co-treated with Camptothecin] results in decreased expression of XIAP protein; [Camptothecin co-treated with FAS protein] results in decreased expression of XIAP protein XIAP protein results in decreased susceptibility to Camptothecin Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein] |
CTD |
PMID:16061681 PMID:16211302 PMID:19633536 PMID:25449198 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
affects response to substance multiple interactions |
ISO |
XRCC1 protein affects the susceptibility to Camptothecin [XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD; olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the susceptibility to Camptothecin] |
CTD |
PMID:35778544 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|
G |
Xrcc3 |
X-ray repair cross complementing 3 |
decreases expression |
ISO |
Camptothecin results in decreased expression of XRCC3 mRNA |
CTD |
PMID:24792648 |
|
NCBI chr 6:130,863,405...130,873,765
Ensembl chr 6:130,863,959...130,872,444
|
|
G |
Xrcc4 |
X-ray repair cross complementing 4 |
decreases response to substance increases methylation |
ISO |
XRCC4 results in decreased susceptibility to Camptothecin Camptothecin results in increased methylation of XRCC4 gene |
CTD |
PMID:21785230 PMID:30720231 |
|
NCBI chr 2:20,948,464...21,197,705
Ensembl chr 2:20,951,200...21,197,808
|
|
G |
Yars2 |
tyrosyl-tRNA synthetase 2 |
increases expression |
ISO |
Camptothecin results in increased expression of YARS2 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr11:84,632,350...84,638,138
Ensembl chr11:84,624,369...84,638,125
|
|
G |
Zap70 |
zeta chain of T cell receptor associated protein kinase 70 |
decreases response to substance |
ISO |
ZAP70 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 9:38,989,750...39,011,701
Ensembl chr 9:38,989,750...39,011,700
|
|
G |
Zc3hc1 |
zinc finger, C3HC-type containing 1 |
decreases response to substance |
ISO |
ZC3HC1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 4:58,989,989...59,011,925
Ensembl chr 4:58,989,987...59,011,933
|
|
G |
Zfp282 |
zinc finger protein 282 |
increases expression |
ISO |
Camptothecin results in increased expression of ZNF282 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 4:76,884,996...76,910,250
Ensembl chr 4:76,884,924...76,911,370
|
|
G |
Zfp383 |
zinc finger protein 383 |
increases expression |
ISO |
Camptothecin results in increased expression of ZNF383 mRNA |
CTD |
PMID:33770205 |
|
|
|